Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Assets (2016 - 2025)

Neurocrine Biosciences' Current Assets history spans 16 years, with the latest figure at $2.5 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 46.27% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $2.5 billion, up 46.27%, while the annual FY2025 figure was $2.5 billion, 46.27% up from the prior year.
  • Current Assets reached $2.5 billion in Q4 2025 per NBIX's latest filing, up from $2.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.5 billion in Q4 2025 to a low of $972.8 million in Q4 2021.
  • Average Current Assets over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2023.
  • Peak YoY movement for Current Assets: decreased 13.07% in 2021, then surged 49.41% in 2022.
  • A 5-year view of Current Assets shows it stood at $972.8 million in 2021, then soared by 49.41% to $1.5 billion in 2022, then rose by 10.56% to $1.6 billion in 2023, then grew by 7.32% to $1.7 billion in 2024, then skyrocketed by 46.27% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Current Assets are $2.5 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.7 billion (Q2 2025).